指南与共识消化道肿瘤与早癌消化内镜

结直肠癌筛查:美国多学会结直肠癌工作组对医生和患者的推荐

Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.
指南 / 共识 · Gastroenterology · 2017-06-09

本文件更新了美国多学会结直肠癌工作组(MSTF)的结直肠癌筛查推荐,该工作组代表美国胃肠病学会、美国胃肠病协会和美国胃肠内镜学会。筛查检测按性能、成本和实用性分为三层:一线为每10年结肠镜和每年粪便免疫化学检测(FIT);二线为每5年CT结肠成像、每3年FIT-粪便DNA检测和每5-10年软式乙状结肠镜;每5年胶囊结肠镜为三线。建议Septin9血清检测不用于筛查。一般风险人群50岁开始筛查,非裔美国人45岁开始;有家族史者按相应条件强化筛查。

要点

  • 一线筛查为每10年结肠镜和每年FIT,二者为筛查基石。
  • 二线包括每5年CT结肠成像、每3年FIT-粪便DNA、每5-10年软式乙状结肠镜。
  • 建议Septin9血清检测不用于筛查(弱推荐)。

核心结论

  • 结肠镜和FIT是筛查的基石,推荐作为首选检测;二线检测也可接受但各有劣势;建议Septin9血清检测不用于筛查。

研究设计与样本

  • 美国多学会结直肠癌工作组(MSTF)制定的指南,代表美国胃肠病学会、美国胃肠病协会和美国胃肠内镜学会。

主要发现

  • 筛查检测按性能、成本和实用性分为三层:一线为每10年结肠镜和每年FIT;二线为每5年CT结肠成像、每3年FIT-粪便DNA检测和每5-10年软式乙状结肠镜;每5年胶囊结肠镜为三线。

关键数值与推荐

  • 一线检测:每10年结肠镜和每年FIT。
  • 二线检测:每5年CT结肠成像、每3年FIT-粪便DNA检测、每5-10年软式乙状结肠镜。
  • 三线检测:每5年胶囊结肠镜。
  • 建议Septin9血清检测不用于筛查(弱推荐)。
  • 一般风险人群50岁开始筛查,非裔美国人45岁开始筛查(有限证据支持)。

临床怎么用

  • 在序贯方案中,先提供结肠镜,拒绝结肠镜者可提供FIT。
  • 多种选项并列时,推荐结肠镜和FIT作为首选检测。
  • 可采取风险分层方法:进展期肿瘤估计低流行人群用FIT筛查,高流行人群用结肠镜筛查。
  • 对疑似结直肠出血的年轻患者推荐进行彻底诊断评估。
  • 筛查及时且既往筛查阴性(尤其是结肠镜)者达75岁或预期寿命<10年时应考虑停止筛查;无既往筛查者根据年龄和合并症考虑筛查至85岁。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This document updates the colorectal cancer (CRC) screening recommendations of the U.S. Multi-Society Task Force of Colorectal Cancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Society for Gastrointestinal Endoscopy. CRC screening tests are ranked in 3 tiers based on performance features, costs, and practical considerations. The first-tier tests are colonoscopy every 10 years and annual fecal immunochemical test (FIT). Colonoscopy and FIT are recommended as the cornerstones of screening regardless of how screening is offered. Thus, in a sequential approach based on colonoscopy offered first, FIT should be offered to patients who decline colonoscopy. Colonoscopy and FIT are recommended as tests of choice when multiple options are presented as alternatives. A risk-stratified approach is also appropriate, with FIT screening in populations with an estimated low prevalence of advanced neoplasia and colonoscopy screening in high prevalence populations. The second-tier tests include CT colonography every 5 years, the FIT-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10 years. These tests are appropriate screening tests, but each has disadvantages relative to the tier 1 tests. Because of limited evidence and current obstacles to use, capsule colonoscopy every 5 years is a third-tier test. We suggest that the Septin9 serum assay (Epigenomics, Seattle, Wash) not be used for screening. Screening should begin at age 50 years in average-risk persons, except in African Americans in whom limited evidence supports screening at 45 years. CRC incidence is rising in persons under age 50, and thorough diagnostic evaluation of young persons with suspected colorectal bleeding is recommended. Discontinuation of screening should be considered when persons up to date with screening, who have prior negative screening (particularly colonoscopy), reach age 75 or have <10 years of life expectancy. Persons without prior screening should be considered for screening up to age 85, depending on age and comorbidities. Persons with a family history of CRC or a documented advanced adenoma in a first-degree relative age <60 years or 2 first-degree relatives with these findings at any age are recommended to undergo screening by colonoscopy every 5 years, beginning 10 years before the age at diagnosis of the youngest affected relative or age 40, whichever is earlier. Persons with a single first-degree relative diagnosed at ≥60 years with CRC or an advanced adenoma can be offered average-risk screening options beginning at age 40 years.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017. PMID: 28600072. doi:10.1053/j.gastro.2017.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。